SEOM guidelines for the management of Malignant Melanoma 2015

about

Comparative safety of BRAF and MEK inhibitors (vemurafenib, dabrafenib and trametinib) in first-line therapy for BRAF-mutated metastatic melanoma.Multidisciplinary management of metastatic melanoma to the inter-atrial septum.

P2860

Q37287433-B383BC98-6368-4026-AF80-7C3B8CDDBE0D Q48093591-572DABE4-ED57-4C96-B643-982F083EF878

P2860

SEOM guidelines for the management of Malignant Melanoma 2015

Item

http://www.wikidata.org/entity/Q36400221

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

SEOM guidelines for the management of Malignant Melanoma 2015

@ast

SEOM guidelines for the management of Malignant Melanoma 2015

@en

type

Item

label

SEOM guidelines for the management of Malignant Melanoma 2015

@ast

SEOM guidelines for the management of Malignant Melanoma 2015

@en

prefLabel

SEOM guidelines for the management of Malignant Melanoma 2015

@ast

SEOM guidelines for the management of Malignant Melanoma 2015

@en

P1476

SEOM guidelines for the management of Malignant Melanoma 2015

@en

P2093

A Berrocal

http://www.w3.org/2001/XMLSchema#string

A G Castaño

http://www.w3.org/2001/XMLSchema#string

A Soria

http://www.w3.org/2001/XMLSchema#string

E Espinosa

http://www.w3.org/2001/XMLSchema#string

I Márquez

http://www.w3.org/2001/XMLSchema#string

J A L Martín

http://www.w3.org/2001/XMLSchema#string

J L G Larriba

http://www.w3.org/2001/XMLSchema#string

M G Cao

http://www.w3.org/2001/XMLSchema#string

S M Algarra

http://www.w3.org/2001/XMLSchema#string

P2860

Interferon alpha for the adjuvant treatment of cutaneous melanoma

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.

Improved overall survival in melanoma with combined dabrafenib and trametinib.

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Nivolumab in previously untreated melanoma without BRAF mutation

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

P2888

s12094-015-1450-4

P304

1030-1035

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12094-015-1450-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ana Arance

P577

2015-12-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

287121246

http://www.w3.org/2001/XMLSchema#string

P698

26669314

http://www.w3.org/2001/XMLSchema#string

P932

4689745

http://www.w3.org/2001/XMLSchema#string

SEOM guidelines for the management of Malignant Melanoma 2015

about

P2860

P2860

SEOM guidelines for the management of Malignant Melanoma 2015

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932